Sugi Predict

Sugi Predict / Compounds / SCHEMBL5956415

SCHEMBL5956415

SCHEMBL5956415

C[C@H](OC(N)=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 1/20 0.58
▸ ALOX5 P09917 2/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ FFAR1 O14842 1/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ SRC P12931 1/20 0.41
▸ LPAR1 Q92633 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27820414 1.00 HCAR2 (0.58) HCAR2ALOX5CYP2D6CYP1A2PKM
SCHEMBL264866 1.00 HCAR2 (0.58) HCAR2ALOX5CYP2D6CYP1A2PKM
SCHEMBL6478149 1.00 HCAR2 (0.58) HCAR2ALOX5CYP2D6CYP1A2PKM
Hydrochloric Acid SCHEMBL27791121 0.98 HCAR2 (0.56) HCAR2ALOX5CYP2D6CYP1A2PKM
Hydrogen Sulfide SCHEMBL27486651 0.98 HCAR2 (0.56) HCAR2ALOX5CYP2D6CYP1A2PKM
Methane SCHEMBL10711774 0.98 HCAR2 (0.56) HCAR2ALOX5CYP2D6CYP1A2PKM
SCHEMBL10520492 0.91 HCAR2 (0.50) HCAR2ALOX5CYP2D6CYP1A2PKM
Acrylic Acid SCHEMBL19712995 0.89 HCAR2 (0.57) HCAR2ALOX5CYP2D6CYP1A2PKM
SCHEMBL14856086 0.89 PTGS2 (0.55) HCAR2ALOX5CYP1A2PKMSMN1; SMN2
SCHEMBL9091695 0.86 PARP10 (0.51) HCAR2ALOX5CYP2D6SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113466389-B Method for obtaining levorotatory muscone by utilizing chromatographic separation technology 宏济堂制药(商河)有限公司 2023-04-07 — — CN claimed
CN-113466389-A Method for obtaining levorotatory muscone by utilizing chromatographic separation technology 山东宏济堂制药集团股份有限公司 2021-10-01 — — CN claimed
EP-1264815-B1 Separating agent for enantiomeric isomers DAICEL CHEM (JP) 2013-03-27 — — EP claimed
EP-2394990-A1 INDOLINE DERIVATIVES Kyoto University (JP) 2011-12-14 — — EP claimed
US-20110294850-A1 INDOLINE DERIVATIVES TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-12-01 — — US claimed
US-20060241163-A1 Optically active (S)-hydantoin derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 — — US claimed
CN-116283557-B Resolution method of S-type and R-type flurbiprofen 江苏汉邦科技股份有限公司 2025-02-25 — — CN disclosed
CN-112867705-B Opioid receptor modulators and products and methods related thereto 埃皮欧黛公司 2024-08-20 — — CN disclosed
CN-118125909-B Method for continuously and industrially preparing levo-muscone 宏济堂制药(商河)有限公司 2024-07-19 — — CN disclosed
CN-118125909-A Method for continuously and industrially preparing levo-muscone 宏济堂制药(商河)有限公司 2024-06-04 — — CN disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-11760736-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-09-19 — — US disclosed
US-11760736-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-09-19 — — US disclosed
US-20060241162-A1 Optically active (R)-hydantoin derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 — — US disclosed
US-20060241163-A1 Optically active (S)-hydantoin derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 — — US disclosed
CN-1136183-C Process for producing optically active mevalonolactone compound ���ƻ�ѧ��ҵ��ʽ���� 2004-01-28 — — CN disclosed
US-20030010696-A1 Separating agent for enantiomeric isomers DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 — — US disclosed
EP-1264815-A2 Separating agent for enantiomeric isomers Daicel Chemical Industries, Ltd. (JP) 2002-12-11 — — EP disclosed
JP-2000302698-A SEPARATING AGENT FOR OPTICAL ISOMER DAICEL CHEM IND LTD 2000-10-31 — — JP disclosed
CN-1141028-A Process for producing optically active mevalonolactone compound DAICEL CHEM (JP) 1997-01-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760736-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 HCAR2 4874/4885ALOX5 3976/4885CYP2D6 4170/4885
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 HCAR2 4611/4885ALOX5 3345/4885CYP2D6 4596/4885
US-20110294850-A1 INDOLINE DERIVATIVES BCHE, ACHE, INMT HCAR2 1034/4885ALOX5 1388/4885CYP2D6 101/4885
US-20060241162-A1 Optically active (R)-hydantoin derivative REN, HTR1F, HCAR1 HCAR2 14/4885ALOX5 522/4885CYP2D6 561/4885
US-20060241163-A1 Optically active (S)-hydantoin derivative REN, ALDH1A2, HPD HCAR2 13/4885ALOX5 479/4885CYP2D6 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.